Beijing Yongtai was founded in China.

Apply to the china national intellectual property administration for a patent on "Highly effective method for amplifying activated lymphocyte and cultivation system".
 

Obtained the patent granted by the china national intellectual property administration for "Highly effective method for amplifying activated lymphocyte and cultivation system";
Preclinical research on EAL ^®.

Start CAR-T cell technology research.
 

Submit an IND application for EAL^® products.

By 2016, EAL^® products have been applied to the clinical treatment of more than 4,000 patients in dozens of hospitals.

The State Drug Administration issued a drug clinical trial approval for EAL^® products; 
Start CAR-T-19 preclinical research on research products.

 
 

EAL^® became the first cell immunotherapy product in China to be approved for Phase II clinical trials, and the first immunocellular product to be approved for Phase II clinical trials for solid tumor treatment;
Conducting Phase II clinical trials of EAL^® products;
CAR-T-19 injections achieved a total remission rate of more than 90% in clinical studies initiated by researchers in research products;
Shanghai Yongtai was established in preparation for the commercialization of EAL^® in eastern China.

Submit an IND application for CAR-T-19 injection product;
Guangzhou Yongrui was established in preparation for the commercialization of EAL^® in southern China;
Set up a research center in Korea for research of CAR-T cell technology;
It has been ethically approved by the China Registered Clinical Trials Ethics Review Committee to conduct clinical studies of CAR-T-19-DNR in research products.

Successfully listed on the Hong Kong Stock Exchange with a net proceeds of HK$1.024 billion;
The New R&D and Industrialisation Base in Beijing obtained real property rights certificate and construction planning permit;
CAR-T-19 Injection obtained clinical trial approval;
EAL@ with liver cancer as indication has completed the enrollment of 272 targeted patients required for the Phase II clinical trial.

Signed the License Agreement with T-CURE , which T-CURE grants company an exclusive license to develop, manufacture or commercialise of the TCR800;
CAR-T-19 Injection held Phase I Clinical Research Kick-off Meeting in Beijing;
Established East China EAL@ Huadong Cellular Immunotherapy Industrial Park and Cellular Immunotherapy Specialised Industry Fund;
6B11-OCIK injection resumed clinical trials.